---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032107"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-10-06T11:45:18+00:00"
generated_at: "2026-10-12T16:36:16.670178+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Valion Bio names Thomas Jensen Board Chair; touts $35.6M government funding for Entolimod ARS program

## Summary
- Thomas H. Jensen named Board Chair of Valion Bio; he is CEO and a director of Nasdaq-listed Allarity Therapeutics, which he has led since December 2023.
- Entolimod is an investigational TLR5 agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS), holding FDA Fast Track and Orphan Drug designations for ARS.
- Entolimod development has received approximately $35.6 million in non-dilutive funding from several U.S. government agencies.
- Jensen said that to the company's knowledge there is no FDA-approved treatment for gastrointestinal ARS; longer term he sees potential in cancer supportive care.
- Jensen is working with Interim CEO Dean Zikria and President/COO/CFO Lisa Wolf; drug supply is controlled through wholly owned U.S.-based CDMO Velocity Bioworks.

## SEC filing metadata
- accession: 0001437749-26-032107
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-10-06T11:45:18+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/0001437749-26-032107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000143774926032107/vbio20261005_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032107
- JSON: https://secwatch.observer/filing/0001437749-26-032107.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.